Abstract
We developed a novel water-soluble camptothecin analogue, CKD602, and evaluated the inhibition of topoisomerase I and the antitumor activities against mammalian tumor cells and human tumor xenografts. CKD602 was a nanomolar inhibitor of the topoisomerase I enzyme in the cleavable complex assay. CKD602 was found to be 3 times and slightly more potent than topotecan and camptothecin as inhibitors of topoisomerase, respectively. In tumor cell cytotoxicity, CKD602 was more potent than topotecan in 14 out of 26 human cancer cell lines tested, while it was comparable to camptothecin. CKD602 was tested for thein vivo antitumor activity against the human tumor xenograft models. CKD602 was able to induce regression of established HT-29, WIDR and CX-1 colon tumors, LX-1 lung tumor, MX-1 breast tumor and SKOV-3 ovarian tumor as much as 80, 94, 76, 67, 87% and 88%, respectively, with comparable body weight changes to those of topotecan. Also the therapeutic margin (R/Emax: maximum tolerance dose/ED58) of CKD602 was significantly higher than that of topotecan by 4 times. Efficacy was determined at the maximal tolerated dose levels using schedule dependent i.p. administration in mice bearing L1210 leukemia. On a Q4d×4 (every 4 day for 4 doses) schedule, the maximum tolerated dose (MTD) was 25 mg/kg per administration, which caused great weight loss and lethality in <5% tumor bearing mouse. This schedule brought significant increase in life span (ILS), 212%, with 33% of long-term survivals. The ex vivo antitumor activity of CKD602 was compared with that of topotecan and the mean antitumor index (ATI) values recorded for CKD602 were significantly higher than that noted for topotecan. From these results, CKD602 warrants further clinical investigations as a potent inhibitor of topoisomerase I.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References Cited
Bodley, A. L. and Liu, L. F. Topoisomerases as novel targets for cancer chemotherapy.Biotechnology, 6, 1315–1319 (1988).
Creaven, P. J., Allen, L. M. and Muggia, F. M. Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity.Cacer, Chemother. Rep., 56, 573–576 (1972).
Drewinko, B., Freireich, E. J. and Gottlieb, J. A. Lethal activity of camptothecin sodium on human lymphoma cells.Cancer Res., 34, 747–750 (1974).
Giovanella, B. C., Stehlin, J. S., Wall, M. E., Wani, M. C., Nicholas, A. W., Liu, L. F., Silber, R. and Potmesil, M. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts.Science, 246, 1046–1048 (1989).
Gottlieb, J. A., Guarino, A. M., Call, J. B., Oliverio, V. and Block, J. B., Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880).Cancer Chemother. Rep., 54, 461–470 (1970).
Gottlieb, J. A., and Luce, J. K. Treatment of malignant melanoma with camptothecin (NSC-100880).Cancer Chemother. Rep., 56, 103–105 (1972).
Hsiang, Y. H. and Liu, L. P. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin.Cancer Res. 48, 1722–1726 (1988).
Hsiang, Y. H., Hertzberg, R., Hech, S. and Liu, L. F. Camptothecin induces protein-lined DNA breaks via mammalian DNA topoisomerase I.J. Biol. Chem., 260, 14873–14878 (1985).
Hsiang, Y. H., Lihou, M. G. and Liu, L. F. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin.Cancer Res., 49, 5077–5082 (1989).
Hsiang, Y. H., Wu, H. Y. and Liu, L. F. Topoisomerases: novel therapeutic targets in cancer chemotherapy.Biochem. Pharmacol., 37, 1801–1085 (1988).
Jew, S. S., Kim, H. J., Kim, M. G., Roh, E. Y., Cho, Y. S., Kim, J. K., Cha, K. H., Lee, K. K., Han, H. J., Choi, J. Y. and Lee, H. S., Synthesis and antitumor activity of 7-substituted 20(RS)-camptothecin analogues.Bioorg. Med. Chem. Lett., 6(7), 845–848 (1996a).
Jew, S. S., Kim, M. G., Kim, H. J., Roh, E. Y., Cho, Y. S., Kim, J. K., Cha, K. H., Lee, K. K., Han, H. J., and Lee, H. S. Synthesis andin vitro cytotoxicity of (RS)-20-desethyl-20-substituted camptothecin analogues.Bioorg. Med. Chem. Lett., 6, 849–852 (1996b).
Jew, S. S., Ok, K. D., Kim, H. J., Kim, M. G., Kim, J. M., Hah, J. M. and Cho, Y. S. Enantioselective synthesis of 20(S)-camptothecin using sharpless catalytic asymmetric dihydroxylation.Tetrahedron: Asymmetry, 6, 1245–1248 (1995).
Kingsbury, W. D., Boehm, J. C., and Jakas, D. R. Synthesis of water-soluble (aminoalkyl)camptothecin analogues: Inhibition of topoisomerase I and antitumor activity.J. Med. Chem., 34, 98–107 (1989).
KRICT report-Part I (unpublished data): Acute toxicity study of CKD-602 in rats (1998).
KRICT report-Part II (unpublished data): 4-weeks subacute toxicity study of CKD-602 in rats. (1998).
Lee, J. H., Sohn, Y. S., Lee, J. M., Kim, J. K., Ahn, S. K., Jew, S. S., Park, J. G., and Hong, C. I. Antitumor activity of CKD602, a novel camptothecin derivative.Proc. Am. Assoc. Cancer Res., 39, 303 (1998).
Li, L. H., Fraser, T. J., Olin, E. J. and Bhuyan, B. K. Action of camptothecin on mammalian cells in culture.Cancer Res., 32, 2643–2650 (1972).
Liu, L. F., Rowe, T. C., Tang, L., Tewey, K. M., and Chen, G. L. Cleavage of DNA by mammalian DNA topoisomerase II.J. Biol. Chem., 258, 15365–15370 (1983).
Moertel, C. G., Scutt, A. J., Reitemeier, R. J., and Hahn, R. G. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer.Cancer Chemother. Rep. 56, 95–101 (1972).
Muggia, F. M., Creaven, P. J., Hansen, H. H., Cohen, M. H., and Selawry, O. S. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-10080): correlation with preclinical studies.Cancer Chemother. Rep., 56, 515–521 (1972).
Patent, publication number: WO96-21666, Camptothecin derivative and its manufacturing method.
Rose, K. M. DNA topoisomerases as targets for chemotherapy.FASEB J., 2, 2474–2479 (1988).
Sasaki, Y., Shinkai, T., Eguchi, K., Tamura, T., Ohe, Y., Ohmori, T. and Saijo, N. Prediction of the antitumor activity of new platinum analogs based on theirex vivo pharmacodynamics as determined by bioassay.Cancer Chemother Pharmacol., 27, 263–270 (1991).
Skipper, H. E., Schabel, F. M. Jr, Mellett, L. B., Montgomerry, J. A., Wilkoff, L. J., Lloyd, H. H. and Brockman, R. W. Implications of biochemical, cytokinetic, pharmacologic and toxicologic relationships in the design of optimal therapeutic schedules.Cancer Chemother. Rep., 54, 431–437 (1970).
Tewey, K. M., Chen, G. L., Nelson, E. M., and Liu, L. F. Interactive antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomeraes II.J. Biol. Chem., 2, 9182–9187 (1984).
Wall, M. E., Wani, M. C., Cook, C. E., Palmer, K. H., Mcphail, A. T., and Sim, G. A., Plant antitumor agents. I: The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibition fromCamptotheca acuminata.J. Am. Chem. Soc., 83, 3888–3894 (1966).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lee, JH., Lee, JM., Kim, JK. et al. Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor. Arch. Pharm. Res. 21, 581–590 (1998). https://doi.org/10.1007/BF02975379
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02975379